Formulary
Sucralfate: Indications, Dosing, Side Effects and Interactions
Sucralfate is a complex of aluminium hydroxide and sulfated sucrose which forms a barrier to protect the mucosa from acid, pepsin and bile attack in gastric...
MedNext Academy | 3 min read
Sucralfate: Indications, Dosing, Side Effects and Interactions
Sucralfate is a complex of aluminium hydroxide and sulfated sucrose which forms a barrier to protect the mucosa from acid, pepsin and bile attack in gastric...
Drug action
Sucralfate is a complex of aluminium hydroxide and sulfated sucrose which forms a barrier to protect the mucosa from acid, pepsin and bile attack in gastric and duodenal ulcers.
Indications and dose
**Benign gastric ulceration,Benign duodenal ulceration**
- **Child** (By Mouth): 15-17 years 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4-6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day.
- **Adult** (By Mouth): 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4-6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day.
**Chronic gastritis**
- **Adult** (By Mouth): 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4-6 weeks or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day.
**Prophylaxis of stress ulceration in child under intensive care**
- **Child** (By Mouth): 15-17 years 1 g 6 times a day; maximum 8 g per day.
**Prophylaxis of stress ulceration**
- **Adult** (By Mouth): 1 g 6 times a day; maximum 8 g per day.
**Benign gastric ulceration, Benign duodenal ulceration for sucralfate**
- **Child 1 month-1 year** (By mouth): 250 mg 4-6 times a day.
- **Child 2-11 years** (By mouth): 500 mg 4-6 times a day.
- **Child 12-14 years** (By mouth): 1 g 4-6 times a day.
- **Child 15-17 years** (By mouth): 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4-6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day.
**Prophylaxis of stress ulceration in child under intensive care for sucralfate**
- **Child 1 month-1 year** (By mouth): 250 mg 4-6 times a day.
- **Child 2-11 years** (By mouth): 500 mg 4-6 times a day.
- **Child 12-14 years** (By mouth): 1 g 4-6 times a day.
- **Child 15-17 years** (By mouth): 1 g 6 times a day; maximum 8 g per day.
Cautions
Patients under intensive care ( Important: reports of bezoar formation) Cautions, further information Bezoar formation Following reports of bezoar formation associated with sucralfate, caution is advised in seriously ill patients, especially those receiving concomitant enteral feeds or those with predisposing conditions such as delayed gastric emptying.
Side effects
Common or very common Constipation Uncommon Dry mouth; nausea Rare or very rare Bezoar; rash Frequency not known Back pain; bone disorders; diarrhoea; dizziness; drowsiness; encephalopathy; flatulence; headache; vertigo
Interactions
**Other interactions (13):**
- Patients taking aluminium- containing preparations (e.g.
- Cholestyramine and sucralfate potentially decrease absorption of Dindevan.
- Calcium or iron supplements (including multivitamins) Other cationcontaining antacids Cationcontaining laxatives Sucralfate Buffered medicinal products Interaction not studied with any of the...
- Sucralfate (Chelation with polyvalent cations) Interaction not studied with any of the components of Biktarvy.
- Antacids or sucralfate: The absorption of sulpiride is decreased after co-administration.
- Absorption of tetracyclines is possibly reduced by kaolin, quinapril tablets (quinapril tablets contain magnesium carbonate), strontium ranelate, sucralfate, tripotassium dicitratobismuthate.
Pregnancy
No evidence of harm; absorption from gastro-intestinal tract negligible.
Breast feeding
Amount probably too small to be harmful.
Renal impairment
Caution (aluminium is absorbed and may accumulate). M
Medicinal forms
Tablet,Tablet,Suspension
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Sucralfate in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

